New CAR t cell therapy takes on Hard-to-Treat ovarian cancer
NCT ID NCT06305299
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new treatment for ovarian cancer that has returned after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goal is to find a safe dose and see what side effects occur.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iC9-CAR.B7-H3 T cells (a type of immune cell therapy)
What this could lead to
If this works, it could point toward a new treatment option for ovarian cancer that has stopped responding to standard chemotherapy.
What could go wrong
This is a very early phase 1 trial with only 27 participants, so it is primarily testing safety, not effectiveness. There are risks of serious side effects like cytokine release syndrome and nerve toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact Email: •••••@•••••
Contact